| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 89 | 2024 | 314 | 18.270 |
Why?
|
| Aortic Valve Stenosis | 89 | 2023 | 476 | 16.250 |
Why?
|
| Heart Valve Prosthesis | 62 | 2023 | 386 | 10.690 |
Why?
|
| Aortic Valve | 73 | 2023 | 581 | 9.580 |
Why?
|
| Platelet Aggregation Inhibitors | 55 | 2024 | 444 | 8.610 |
Why?
|
| Percutaneous Coronary Intervention | 38 | 2024 | 342 | 8.610 |
Why?
|
| Heart Valve Prosthesis Implantation | 55 | 2024 | 563 | 8.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 61 | 2018 | 314 | 6.180 |
Why?
|
| Coronary Artery Disease | 50 | 2023 | 1011 | 5.870 |
Why?
|
| Blood Platelets | 27 | 2018 | 731 | 5.030 |
Why?
|
| Acute Coronary Syndrome | 27 | 2021 | 259 | 5.010 |
Why?
|
| Mitral Valve Insufficiency | 23 | 2024 | 180 | 4.850 |
Why?
|
| Ticlopidine | 23 | 2021 | 95 | 4.800 |
Why?
|
| Drug-Eluting Stents | 32 | 2023 | 131 | 4.260 |
Why?
|
| Cardiac Catheterization | 35 | 2024 | 687 | 4.210 |
Why?
|
| Bioprosthesis | 23 | 2023 | 167 | 3.790 |
Why?
|
| Myocardial Infarction | 55 | 2023 | 1374 | 3.550 |
Why?
|
| Thrombosis | 22 | 2023 | 781 | 3.360 |
Why?
|
| Platelet Aggregation | 20 | 2014 | 257 | 3.010 |
Why?
|
| Stents | 27 | 2021 | 1096 | 2.760 |
Why?
|
| Stroke | 27 | 2023 | 1144 | 2.540 |
Why?
|
| Treatment Outcome | 169 | 2024 | 32848 | 2.190 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 26 | 2016 | 100 | 2.160 |
Why?
|
| Anticoagulants | 27 | 2021 | 787 | 2.110 |
Why?
|
| Aortic Valve Insufficiency | 10 | 2023 | 167 | 2.070 |
Why?
|
| Prosthesis Failure | 10 | 2023 | 206 | 2.020 |
Why?
|
| Aspirin | 15 | 2010 | 455 | 2.010 |
Why?
|
| Prosthesis Design | 37 | 2023 | 749 | 1.880 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 719 | 1.830 |
Why?
|
| Fibrinolytic Agents | 17 | 2021 | 324 | 1.790 |
Why?
|
| Mitral Valve | 18 | 2023 | 271 | 1.760 |
Why?
|
| Heart Valve Diseases | 6 | 2023 | 193 | 1.760 |
Why?
|
| Hemorrhage | 22 | 2020 | 712 | 1.590 |
Why?
|
| Humans | 328 | 2024 | 261506 | 1.550 |
Why?
|
| Postoperative Complications | 38 | 2023 | 5542 | 1.510 |
Why?
|
| Myocardial Revascularization | 11 | 2021 | 134 | 1.460 |
Why?
|
| Risk Factors | 90 | 2023 | 17523 | 1.390 |
Why?
|
| Mortality | 9 | 2021 | 343 | 1.360 |
Why?
|
| Mitral Valve Annuloplasty | 4 | 2021 | 22 | 1.360 |
Why?
|
| Heparin | 21 | 2014 | 360 | 1.330 |
Why?
|
| Registries | 33 | 2024 | 2170 | 1.280 |
Why?
|
| Hemodynamics | 19 | 2023 | 935 | 1.250 |
Why?
|
| Coronary Thrombosis | 7 | 2017 | 44 | 1.250 |
Why?
|
| Coronary Disease | 15 | 2011 | 764 | 1.230 |
Why?
|
| Hospital Mortality | 17 | 2022 | 1274 | 1.170 |
Why?
|
| Coronary Angiography | 24 | 2023 | 598 | 1.150 |
Why?
|
| Coronary Artery Bypass | 16 | 2022 | 708 | 1.120 |
Why?
|
| Mitral Valve Stenosis | 4 | 2021 | 50 | 1.100 |
Why?
|
| Shock, Cardiogenic | 7 | 2021 | 228 | 1.080 |
Why?
|
| Aged | 159 | 2024 | 70117 | 1.070 |
Why?
|
| Tricuspid Valve Insufficiency | 6 | 2024 | 67 | 1.070 |
Why?
|
| Male | 199 | 2024 | 123000 | 1.060 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2021 | 1237 | 1.050 |
Why?
|
| von Willebrand Factor | 3 | 2018 | 335 | 1.040 |
Why?
|
| Female | 198 | 2024 | 141928 | 1.000 |
Why?
|
| Platelet Function Tests | 6 | 2021 | 50 | 0.990 |
Why?
|
| Platelet Activation | 13 | 2013 | 116 | 0.990 |
Why?
|
| Time Factors | 62 | 2022 | 12926 | 0.980 |
Why?
|
| Ultrasonography, Interventional | 4 | 2023 | 429 | 0.970 |
Why?
|
| Drug Resistance | 7 | 2018 | 587 | 0.950 |
Why?
|
| Atrial Appendage | 1 | 2024 | 55 | 0.930 |
Why?
|
| Postoperative Hemorrhage | 5 | 2021 | 162 | 0.910 |
Why?
|
| Enoxaparin | 13 | 2013 | 66 | 0.890 |
Why?
|
| Peptides | 12 | 2014 | 1479 | 0.880 |
Why?
|
| Myocardial Ischemia | 10 | 2022 | 435 | 0.880 |
Why?
|
| Peptide Fragments | 13 | 2014 | 1271 | 0.860 |
Why?
|
| Aged, 80 and over | 72 | 2024 | 29902 | 0.840 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2021 | 435 | 0.840 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2021 | 255 | 0.830 |
Why?
|
| Pacemaker, Artificial | 4 | 2021 | 213 | 0.820 |
Why?
|
| Platelet Count | 7 | 2016 | 490 | 0.810 |
Why?
|
| Heart Ventricles | 4 | 2023 | 846 | 0.780 |
Why?
|
| Femoral Artery | 4 | 2019 | 210 | 0.780 |
Why?
|
| Tomography, Optical Coherence | 2 | 2023 | 501 | 0.750 |
Why?
|
| Cardiologists | 1 | 2021 | 33 | 0.750 |
Why?
|
| Betacoronavirus | 3 | 2020 | 527 | 0.750 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 651 | 0.730 |
Why?
|
| Hirudins | 13 | 2014 | 65 | 0.730 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 715 | 0.720 |
Why?
|
| Severity of Illness Index | 29 | 2023 | 4320 | 0.710 |
Why?
|
| Acute Kidney Injury | 6 | 2022 | 739 | 0.710 |
Why?
|
| Blood Loss, Surgical | 2 | 2021 | 309 | 0.710 |
Why?
|
| Heart Diseases | 3 | 2020 | 732 | 0.700 |
Why?
|
| Risk Assessment | 29 | 2021 | 6869 | 0.690 |
Why?
|
| P-Selectin | 9 | 2010 | 124 | 0.680 |
Why?
|
| Coronary Vessels | 5 | 2016 | 665 | 0.660 |
Why?
|
| Middle Aged | 121 | 2024 | 86204 | 0.630 |
Why?
|
| Calcinosis | 2 | 2023 | 423 | 0.630 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 7 | 0.620 |
Why?
|
| Prospective Studies | 47 | 2023 | 12873 | 0.620 |
Why?
|
| Coronary Occlusion | 1 | 2018 | 31 | 0.620 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2019 | 303 | 0.600 |
Why?
|
| Off-Label Use | 1 | 2017 | 46 | 0.600 |
Why?
|
| Bundle-Branch Block | 5 | 2021 | 43 | 0.600 |
Why?
|
| Creatine Kinase, MB Form | 8 | 2019 | 29 | 0.600 |
Why?
|
| Ventricular Function | 1 | 2018 | 93 | 0.600 |
Why?
|
| Telemedicine | 2 | 2020 | 471 | 0.590 |
Why?
|
| Monitoring, Physiologic | 2 | 2020 | 502 | 0.590 |
Why?
|
| Recovery of Function | 10 | 2020 | 703 | 0.590 |
Why?
|
| Excipients | 1 | 2016 | 17 | 0.580 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 50 | 0.580 |
Why?
|
| Intracranial Embolism | 1 | 2016 | 39 | 0.570 |
Why?
|
| Patient Selection | 10 | 2022 | 2055 | 0.560 |
Why?
|
| Incidence | 21 | 2022 | 5673 | 0.560 |
Why?
|
| United States | 46 | 2023 | 15433 | 0.560 |
Why?
|
| Antithrombins | 7 | 2011 | 74 | 0.550 |
Why?
|
| Radiation Exposure | 1 | 2017 | 73 | 0.550 |
Why?
|
| Coronary Stenosis | 3 | 2019 | 117 | 0.540 |
Why?
|
| Sinus Arrest, Cardiac | 1 | 2015 | 3 | 0.540 |
Why?
|
| Patient Readmission | 5 | 2022 | 548 | 0.530 |
Why?
|
| Brugada Syndrome | 1 | 2015 | 18 | 0.530 |
Why?
|
| Brain Ischemia | 1 | 2018 | 292 | 0.530 |
Why?
|
| Pandemics | 4 | 2020 | 1559 | 0.520 |
Why?
|
| Heart-Assist Devices | 4 | 2019 | 1171 | 0.520 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2022 | 2594 | 0.520 |
Why?
|
| Radial Artery | 1 | 2015 | 50 | 0.510 |
Why?
|
| Follow-Up Studies | 41 | 2023 | 14889 | 0.510 |
Why?
|
| Intra-Aortic Balloon Pumping | 4 | 2019 | 69 | 0.510 |
Why?
|
| Erythrocytes | 2 | 2013 | 339 | 0.510 |
Why?
|
| Recombinant Proteins | 14 | 2014 | 2927 | 0.510 |
Why?
|
| Flow Cytometry | 6 | 2016 | 3033 | 0.500 |
Why?
|
| Angina Pectoris | 6 | 2008 | 80 | 0.500 |
Why?
|
| Ethanol | 4 | 2021 | 264 | 0.500 |
Why?
|
| Coronary Restenosis | 8 | 2017 | 63 | 0.500 |
Why?
|
| Stem Cells | 3 | 2018 | 1213 | 0.490 |
Why?
|
| Heart Failure | 10 | 2024 | 2516 | 0.480 |
Why?
|
| Echocardiography | 14 | 2024 | 1182 | 0.480 |
Why?
|
| Sirolimus | 4 | 2012 | 814 | 0.470 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2004 | 99 | 0.470 |
Why?
|
| Cause of Death | 9 | 2021 | 752 | 0.450 |
Why?
|
| Membrane Glycoproteins | 5 | 2007 | 1073 | 0.430 |
Why?
|
| Cardiovascular Diseases | 6 | 2018 | 2195 | 0.430 |
Why?
|
| Drug Discovery | 1 | 2015 | 324 | 0.430 |
Why?
|
| Automation, Laboratory | 1 | 2012 | 27 | 0.420 |
Why?
|
| Paclitaxel | 6 | 2010 | 1996 | 0.410 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 49 | 0.410 |
Why?
|
| Brachytherapy | 1 | 2018 | 977 | 0.410 |
Why?
|
| Coronary Aneurysm | 1 | 2012 | 36 | 0.410 |
Why?
|
| Predictive Value of Tests | 15 | 2023 | 4892 | 0.400 |
Why?
|
| Electrocardiography | 10 | 2021 | 1145 | 0.400 |
Why?
|
| Heart Conduction System | 3 | 2021 | 165 | 0.390 |
Why?
|
| Surgeons | 2 | 2017 | 519 | 0.390 |
Why?
|
| Cardiovascular Agents | 5 | 2017 | 128 | 0.390 |
Why?
|
| Operating Rooms | 1 | 2012 | 122 | 0.380 |
Why?
|
| Hemostasis | 1 | 2011 | 109 | 0.380 |
Why?
|
| Troponin | 2 | 2012 | 92 | 0.380 |
Why?
|
| Stroke Volume | 6 | 2023 | 577 | 0.380 |
Why?
|
| Receptors, Purinergic P2 | 2 | 2008 | 28 | 0.370 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 115 | 0.360 |
Why?
|
| Angina, Unstable | 6 | 2008 | 70 | 0.360 |
Why?
|
| Ventricular Function, Left | 7 | 2023 | 603 | 0.350 |
Why?
|
| Prasugrel Hydrochloride | 3 | 2019 | 25 | 0.350 |
Why?
|
| Ventricular Outflow Obstruction | 2 | 2021 | 88 | 0.350 |
Why?
|
| Drug Tolerance | 2 | 2010 | 114 | 0.350 |
Why?
|
| Catheterization, Peripheral | 3 | 2019 | 158 | 0.350 |
Why?
|
| Drug Therapy, Combination | 14 | 2010 | 2315 | 0.350 |
Why?
|
| Balloon Valvuloplasty | 2 | 2021 | 31 | 0.350 |
Why?
|
| Magnetics | 2 | 2007 | 107 | 0.340 |
Why?
|
| Cell Adhesion Molecules | 4 | 2013 | 577 | 0.340 |
Why?
|
| Arachidonic Acid | 2 | 2010 | 118 | 0.340 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.340 |
Why?
|
| Frailty | 2 | 2021 | 113 | 0.330 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 135 | 0.330 |
Why?
|
| Triage | 2 | 2020 | 252 | 0.320 |
Why?
|
| Immunosuppressive Agents | 3 | 2012 | 1375 | 0.320 |
Why?
|
| Heart Rate | 3 | 2021 | 737 | 0.320 |
Why?
|
| Length of Stay | 9 | 2022 | 1900 | 0.320 |
Why?
|
| Pipecolic Acids | 2 | 2004 | 13 | 0.320 |
Why?
|
| Cardiology | 4 | 2020 | 530 | 0.320 |
Why?
|
| Tricuspid Valve | 2 | 2019 | 68 | 0.320 |
Why?
|
| Vascular Diseases | 2 | 2015 | 246 | 0.310 |
Why?
|
| Diabetes Complications | 2 | 2009 | 305 | 0.310 |
Why?
|
| Catheter Ablation | 3 | 2021 | 620 | 0.310 |
Why?
|
| Proportional Hazards Models | 12 | 2020 | 4988 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 11 | 2011 | 4367 | 0.310 |
Why?
|
| Patient Discharge | 4 | 2021 | 661 | 0.310 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2019 | 66 | 0.300 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 66 | 0.300 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2019 | 127 | 0.300 |
Why?
|
| Angioplasty | 4 | 2011 | 94 | 0.300 |
Why?
|
| Kidney Failure, Chronic | 4 | 2018 | 960 | 0.300 |
Why?
|
| Caffeine | 1 | 2007 | 87 | 0.300 |
Why?
|
| Vasodilation | 1 | 2008 | 205 | 0.300 |
Why?
|
| Ranitidine | 1 | 2006 | 35 | 0.300 |
Why?
|
| Propensity Score | 7 | 2020 | 750 | 0.290 |
Why?
|
| Histamine H2 Antagonists | 1 | 2006 | 50 | 0.290 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 487 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 521 | 0.280 |
Why?
|
| Integrin beta3 | 1 | 2006 | 44 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2020 | 6207 | 0.280 |
Why?
|
| Retrospective Studies | 27 | 2023 | 37905 | 0.280 |
Why?
|
| Research Design | 4 | 2017 | 1544 | 0.270 |
Why?
|
| Comorbidity | 8 | 2020 | 2352 | 0.270 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 117 | 0.260 |
Why?
|
| Clinical Decision-Making | 3 | 2018 | 524 | 0.260 |
Why?
|
| Adult | 31 | 2022 | 77950 | 0.260 |
Why?
|
| Regression Analysis | 3 | 2022 | 1546 | 0.260 |
Why?
|
| Drug Delivery Systems | 3 | 2006 | 669 | 0.260 |
Why?
|
| Drug Resistance, Multiple | 1 | 2005 | 204 | 0.260 |
Why?
|
| Radiography, Interventional | 3 | 2015 | 305 | 0.260 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2017 | 68 | 0.250 |
Why?
|
| Multidetector Computed Tomography | 5 | 2018 | 150 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2011 | 4938 | 0.250 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2019 | 126 | 0.250 |
Why?
|
| CD40 Ligand | 2 | 2011 | 115 | 0.240 |
Why?
|
| Mercury | 1 | 2024 | 32 | 0.240 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 481 | 0.230 |
Why?
|
| Metals | 3 | 2013 | 155 | 0.230 |
Why?
|
| Phosphoproteins | 2 | 2013 | 1152 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 6 | 2019 | 543 | 0.230 |
Why?
|
| Health Services | 1 | 2024 | 105 | 0.230 |
Why?
|
| Troponin T | 2 | 2019 | 261 | 0.230 |
Why?
|
| Macrophage-1 Antigen | 1 | 2003 | 51 | 0.230 |
Why?
|
| Endovascular Procedures | 2 | 2021 | 516 | 0.230 |
Why?
|
| Infusions, Intravenous | 10 | 2021 | 1382 | 0.220 |
Why?
|
| Double-Blind Method | 17 | 2018 | 2588 | 0.220 |
Why?
|
| Embolism | 1 | 2023 | 59 | 0.220 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 160 | 0.220 |
Why?
|
| Inpatients | 5 | 2019 | 678 | 0.220 |
Why?
|
| Fluoroscopy | 3 | 2021 | 232 | 0.220 |
Why?
|
| Hospital Costs | 3 | 2017 | 228 | 0.210 |
Why?
|
| Monocytes | 2 | 2005 | 788 | 0.210 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 136 | 0.210 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 250 | 0.210 |
Why?
|
| Thrombolytic Therapy | 2 | 2007 | 257 | 0.210 |
Why?
|
| Contrast Media | 3 | 2022 | 1472 | 0.210 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2018 | 192 | 0.210 |
Why?
|
| Pulmonary Veins | 2 | 2021 | 174 | 0.210 |
Why?
|
| Patient Care Planning | 1 | 2004 | 297 | 0.200 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 1450 | 0.200 |
Why?
|
| Saphenous Vein | 2 | 2012 | 95 | 0.200 |
Why?
|
| Vitamin K | 1 | 2021 | 54 | 0.200 |
Why?
|
| Patients | 1 | 2024 | 245 | 0.200 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2021 | 71 | 0.200 |
Why?
|
| Carotid Artery, External | 1 | 2021 | 14 | 0.200 |
Why?
|
| Punctures | 5 | 2019 | 104 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 55 | 0.200 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 78 | 0.200 |
Why?
|
| Heart Arrest | 2 | 2022 | 358 | 0.190 |
Why?
|
| Wales | 1 | 2020 | 7 | 0.190 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 577 | 0.190 |
Why?
|
| Single-Chain Antibodies | 2 | 2011 | 62 | 0.190 |
Why?
|
| Walking Speed | 1 | 2020 | 17 | 0.190 |
Why?
|
| Biomarkers | 8 | 2019 | 5047 | 0.190 |
Why?
|
| England | 1 | 2020 | 75 | 0.190 |
Why?
|
| Reoperation | 6 | 2017 | 1382 | 0.190 |
Why?
|
| Heart Failure, Systolic | 1 | 2020 | 32 | 0.190 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 91 | 0.190 |
Why?
|
| Nursing Homes | 1 | 2021 | 99 | 0.190 |
Why?
|
| Receptors, Purinergic P2Y12 | 3 | 2013 | 15 | 0.190 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 1697 | 0.180 |
Why?
|
| Vena Cava, Superior | 1 | 2020 | 78 | 0.180 |
Why?
|
| Erythrocyte Transfusion | 2 | 2020 | 212 | 0.180 |
Why?
|
| Absorbable Implants | 2 | 2017 | 65 | 0.180 |
Why?
|
| Angina, Stable | 1 | 2019 | 6 | 0.180 |
Why?
|
| Feasibility Studies | 7 | 2023 | 2292 | 0.180 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 10 | 0.180 |
Why?
|
| Risk | 8 | 2022 | 1972 | 0.180 |
Why?
|
| Hospitalization | 10 | 2022 | 2083 | 0.180 |
Why?
|
| Physical Fitness | 1 | 2020 | 122 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 103 | 0.180 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2020 | 53 | 0.180 |
Why?
|
| Single-Blind Method | 3 | 2020 | 409 | 0.180 |
Why?
|
| Adenosine Monophosphate | 2 | 2009 | 76 | 0.180 |
Why?
|
| Cohort Studies | 11 | 2020 | 9244 | 0.180 |
Why?
|
| Heparin, Low-Molecular-Weight | 3 | 2010 | 66 | 0.180 |
Why?
|
| Atherectomy, Coronary | 2 | 2013 | 16 | 0.180 |
Why?
|
| Diffusion of Innovation | 2 | 2018 | 160 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2020 | 787 | 0.180 |
Why?
|
| Subclavian Artery | 3 | 2014 | 80 | 0.180 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2021 | 105 | 0.170 |
Why?
|
| Coronary Circulation | 5 | 2013 | 253 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2021 | 1544 | 0.170 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2018 | 12 | 0.170 |
Why?
|
| Liver Diseases | 2 | 2021 | 574 | 0.170 |
Why?
|
| Hospitals | 2 | 2013 | 485 | 0.170 |
Why?
|
| Cell Count | 2 | 2018 | 508 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 3 | 2018 | 602 | 0.170 |
Why?
|
| Thrombectomy | 1 | 2019 | 158 | 0.170 |
Why?
|
| Survival Rate | 14 | 2019 | 12221 | 0.170 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2018 | 66 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2019 | 179 | 0.160 |
Why?
|
| Clinical Trials as Topic | 5 | 2017 | 3719 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2021 | 7551 | 0.160 |
Why?
|
| Bayes Theorem | 5 | 2022 | 1021 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2020 | 191 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 755 | 0.160 |
Why?
|
| Aortography | 1 | 2018 | 181 | 0.160 |
Why?
|
| Thrombocytopenia | 3 | 2009 | 846 | 0.160 |
Why?
|
| Pilot Projects | 7 | 2021 | 2803 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 3 | 2003 | 257 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2020 | 324 | 0.160 |
Why?
|
| Quality of Life | 7 | 2021 | 4532 | 0.150 |
Why?
|
| Polymers | 2 | 2017 | 223 | 0.150 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2017 | 11 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2019 | 148 | 0.150 |
Why?
|
| Prognosis | 18 | 2021 | 21713 | 0.150 |
Why?
|
| Touch | 1 | 2017 | 71 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 53 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 1054 | 0.150 |
Why?
|
| Acute Disease | 7 | 2015 | 2422 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 925 | 0.150 |
Why?
|
| Acetylcysteine | 1 | 2018 | 143 | 0.150 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2009 | 136 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 1085 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 77 | 0.140 |
Why?
|
| Forecasting | 3 | 2017 | 694 | 0.140 |
Why?
|
| Financial Management | 1 | 2016 | 20 | 0.140 |
Why?
|
| Pericardium | 1 | 2018 | 157 | 0.140 |
Why?
|
| Factor Xa Inhibitors | 2 | 2011 | 70 | 0.140 |
Why?
|
| Erythrocyte Count | 2 | 2013 | 38 | 0.140 |
Why?
|
| Arm | 1 | 2017 | 147 | 0.140 |
Why?
|
| Databases, Factual | 6 | 2021 | 2218 | 0.140 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 329 | 0.140 |
Why?
|
| Automation | 1 | 2016 | 151 | 0.140 |
Why?
|
| Benzothiazoles | 1 | 2016 | 94 | 0.140 |
Why?
|
| Health Resources | 1 | 2017 | 168 | 0.140 |
Why?
|
| Accreditation | 1 | 2016 | 126 | 0.140 |
Why?
|
| Multivariate Analysis | 7 | 2013 | 4298 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 267 | 0.130 |
Why?
|
| Heart Aneurysm | 1 | 2016 | 42 | 0.130 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2015 | 12 | 0.130 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 51 | 0.130 |
Why?
|
| Hematopoiesis | 1 | 2018 | 560 | 0.130 |
Why?
|
| Blood Transfusion | 4 | 2013 | 583 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2012 | 118 | 0.130 |
Why?
|
| Animals | 12 | 2023 | 59536 | 0.130 |
Why?
|
| Suture Techniques | 1 | 2017 | 319 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 610 | 0.130 |
Why?
|
| Antioxidants | 1 | 2018 | 507 | 0.130 |
Why?
|
| Syndrome | 7 | 2006 | 1351 | 0.130 |
Why?
|
| Ventricular Septum | 1 | 2014 | 19 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 473 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.120 |
Why?
|
| Renal Dialysis | 2 | 2018 | 945 | 0.120 |
Why?
|
| Platelet Adhesiveness | 2 | 2005 | 57 | 0.120 |
Why?
|
| Sex Factors | 3 | 2017 | 2139 | 0.120 |
Why?
|
| Aneurysm, False | 1 | 2016 | 153 | 0.120 |
Why?
|
| Adenosine Diphosphate | 3 | 2010 | 113 | 0.120 |
Why?
|
| Exercise Test | 3 | 2012 | 312 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1303 | 0.120 |
Why?
|
| Thrombin | 2 | 2005 | 99 | 0.120 |
Why?
|
| Drug Synergism | 2 | 2007 | 1313 | 0.120 |
Why?
|
| Survival Analysis | 13 | 2019 | 9180 | 0.120 |
Why?
|
| Premedication | 2 | 2011 | 135 | 0.120 |
Why?
|
| Vena Cava Filters | 1 | 2014 | 88 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2013 | 22 | 0.110 |
Why?
|
| Kidney | 2 | 2021 | 2146 | 0.110 |
Why?
|
| Drug Dosage Calculations | 2 | 2011 | 50 | 0.110 |
Why?
|
| Cell Size | 2 | 2010 | 136 | 0.110 |
Why?
|
| Aorta | 2 | 2014 | 692 | 0.110 |
Why?
|
| Quinolines | 1 | 2016 | 383 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 190 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2020 | 6100 | 0.110 |
Why?
|
| Health Status | 2 | 2015 | 590 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 500 | 0.110 |
Why?
|
| Catheters | 2 | 2024 | 126 | 0.110 |
Why?
|
| Durapatite | 1 | 2012 | 31 | 0.110 |
Why?
|
| Chi-Square Distribution | 5 | 2016 | 1323 | 0.110 |
Why?
|
| Thiophenes | 1 | 2013 | 148 | 0.110 |
Why?
|
| Logistic Models | 7 | 2019 | 3441 | 0.110 |
Why?
|
| Thromboxane B2 | 2 | 2010 | 27 | 0.110 |
Why?
|
| Canada | 3 | 2020 | 429 | 0.110 |
Why?
|
| Treatment Failure | 3 | 2015 | 1391 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 361 | 0.110 |
Why?
|
| Cross-Over Studies | 3 | 2011 | 460 | 0.110 |
Why?
|
| Blood Coagulation | 2 | 2003 | 185 | 0.110 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 180 | 0.110 |
Why?
|
| Materials Testing | 1 | 2012 | 116 | 0.110 |
Why?
|
| Surgical Instruments | 2 | 2023 | 138 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 160 | 0.100 |
Why?
|
| Vascular Grafting | 1 | 2012 | 50 | 0.100 |
Why?
|
| Europe | 3 | 2020 | 649 | 0.100 |
Why?
|
| Selection Bias | 1 | 2011 | 50 | 0.100 |
Why?
|
| Piperazines | 2 | 2013 | 2101 | 0.100 |
Why?
|
| Minor Surgical Procedures | 1 | 2011 | 4 | 0.100 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2011 | 3 | 0.100 |
Why?
|
| Leukocytes | 2 | 2004 | 422 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2010 | 852 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2008 | 1048 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2013 | 263 | 0.100 |
Why?
|
| Texas | 4 | 2015 | 6311 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2011 | 126 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2014 | 3472 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4549 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2013 | 477 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 660 | 0.090 |
Why?
|
| Receptors, Thrombin | 2 | 2007 | 23 | 0.090 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 8865 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 671 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 1618 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.090 |
Why?
|
| Device Removal | 3 | 2024 | 337 | 0.090 |
Why?
|
| Reference Values | 2 | 2011 | 1099 | 0.090 |
Why?
|
| Collagen | 3 | 2008 | 752 | 0.090 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2010 | 110 | 0.090 |
Why?
|
| Solubility | 3 | 2005 | 242 | 0.090 |
Why?
|
| Age Factors | 6 | 2019 | 5377 | 0.090 |
Why?
|
| Lipoproteins | 1 | 2011 | 252 | 0.090 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2009 | 46 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2003 | 5270 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 499 | 0.090 |
Why?
|
| Recurrence | 4 | 2021 | 4758 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2013 | 739 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 83 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 4744 | 0.080 |
Why?
|
| Receptors, Thromboxane | 1 | 2008 | 7 | 0.080 |
Why?
|
| Factor IXa | 1 | 2008 | 1 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 622 | 0.080 |
Why?
|
| Computer Systems | 1 | 2008 | 106 | 0.080 |
Why?
|
| Cyclooxygenase 1 | 1 | 2008 | 67 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 1270 | 0.080 |
Why?
|
| Retreatment | 4 | 2012 | 452 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2009 | 142 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 462 | 0.080 |
Why?
|
| Protein Kinase C-delta | 1 | 2008 | 42 | 0.080 |
Why?
|
| Adenoviridae | 2 | 2003 | 1459 | 0.080 |
Why?
|
| Aptamers, Nucleotide | 1 | 2008 | 62 | 0.080 |
Why?
|
| Genetic Therapy | 3 | 2007 | 1616 | 0.080 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2007 | 27 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 1489 | 0.080 |
Why?
|
| Morbidity | 2 | 2019 | 397 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 177 | 0.080 |
Why?
|
| omega-N-Methylarginine | 1 | 2007 | 34 | 0.080 |
Why?
|
| Global Health | 3 | 2019 | 657 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2007 | 26 | 0.080 |
Why?
|
| Hydrazones | 1 | 2007 | 42 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4078 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 6009 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2008 | 227 | 0.070 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 234 | 0.070 |
Why?
|
| Intermittent Claudication | 1 | 2007 | 56 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2008 | 553 | 0.070 |
Why?
|
| Radiography | 1 | 2011 | 1904 | 0.070 |
Why?
|
| Calcium | 2 | 2023 | 1537 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 546 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 383 | 0.070 |
Why?
|
| India | 1 | 2007 | 301 | 0.070 |
Why?
|
| Blood Coagulation Factors | 2 | 2003 | 59 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2012 | 795 | 0.070 |
Why?
|
| Genetic Vectors | 3 | 2007 | 1694 | 0.070 |
Why?
|
| Pyridines | 1 | 2013 | 1244 | 0.070 |
Why?
|
| Ventricular Remodeling | 2 | 2020 | 248 | 0.070 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Hirudin Therapy | 2 | 2004 | 4 | 0.070 |
Why?
|
| Basement Membrane | 1 | 2006 | 138 | 0.070 |
Why?
|
| Thromboplastin | 1 | 2006 | 34 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2007 | 314 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2014 | 3890 | 0.070 |
Why?
|
| Antigens, CD | 3 | 2006 | 1385 | 0.070 |
Why?
|
| Embolic Protection Devices | 2 | 2018 | 5 | 0.070 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2007 | 163 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 429 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 375 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2010 | 667 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 849 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 4757 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 598 | 0.070 |
Why?
|
| Collateral Circulation | 1 | 2005 | 59 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 1375 | 0.070 |
Why?
|
| Sternotomy | 2 | 2015 | 58 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2017 | 2316 | 0.060 |
Why?
|
| Apyrase | 1 | 2005 | 44 | 0.060 |
Why?
|
| Plasmids | 1 | 2007 | 837 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 353 | 0.060 |
Why?
|
| Hemostasis, Surgical | 1 | 2005 | 48 | 0.060 |
Why?
|
| Phosphatidylserines | 1 | 2005 | 68 | 0.060 |
Why?
|
| Kidney Diseases | 2 | 2008 | 691 | 0.060 |
Why?
|
| Vascular Fistula | 1 | 2004 | 41 | 0.060 |
Why?
|
| Arginine | 2 | 2004 | 500 | 0.060 |
Why?
|
| Sinus of Valsalva | 1 | 2004 | 53 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 235 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2021 | 305 | 0.060 |
Why?
|
| Thoracotomy | 2 | 2015 | 220 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2003 | 55 | 0.060 |
Why?
|
| Heart Valves | 1 | 2024 | 66 | 0.060 |
Why?
|
| Echocardiography, Stress | 1 | 2023 | 24 | 0.060 |
Why?
|
| Dobutamine | 1 | 2023 | 54 | 0.060 |
Why?
|
| Health Facilities | 1 | 2024 | 79 | 0.060 |
Why?
|
| Cell Movement | 2 | 2008 | 2466 | 0.060 |
Why?
|
| Whole Blood Coagulation Time | 3 | 2011 | 16 | 0.060 |
Why?
|
| Fibrinolysis | 1 | 2003 | 63 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 329 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2003 | 106 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2004 | 259 | 0.050 |
Why?
|
| Death | 1 | 2023 | 119 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 310 | 0.050 |
Why?
|
| Algorithms | 3 | 2009 | 3890 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2008 | 4804 | 0.050 |
Why?
|
| Propionates | 1 | 2002 | 71 | 0.050 |
Why?
|
| Plasma | 1 | 2003 | 158 | 0.050 |
Why?
|
| Developing Countries | 1 | 2004 | 315 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2006 | 636 | 0.050 |
Why?
|
| Assisted Circulation | 1 | 2021 | 37 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2002 | 83 | 0.050 |
Why?
|
| Ischemia | 2 | 2021 | 391 | 0.050 |
Why?
|
| Observer Variation | 2 | 2015 | 671 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 376 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 783 | 0.050 |
Why?
|
| Patient Safety | 2 | 2020 | 649 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 223 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2003 | 196 | 0.050 |
Why?
|
| Prevalence | 3 | 2020 | 3260 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 945 | 0.050 |
Why?
|
| Proteomics | 1 | 2008 | 1380 | 0.050 |
Why?
|
| Pancreas Transplantation | 1 | 2020 | 46 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2021 | 129 | 0.050 |
Why?
|
| Tachycardia | 1 | 2020 | 70 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2007 | 1529 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 301 | 0.050 |
Why?
|
| Echocardiography, Four-Dimensional | 1 | 2020 | 17 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 4109 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2011 | 573 | 0.040 |
Why?
|
| Gadolinium | 1 | 2020 | 164 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 95 | 0.040 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 64 | 0.040 |
Why?
|
| Prescriptions | 1 | 2019 | 65 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 1879 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2003 | 644 | 0.040 |
Why?
|
| Solvents | 1 | 2019 | 66 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2003 | 411 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 1242 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 891 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 586 | 0.040 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 69 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 108 | 0.040 |
Why?
|
| Cicatrix | 1 | 2020 | 208 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2007 | 2022 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2004 | 1823 | 0.040 |
Why?
|
| Connectin | 1 | 2018 | 30 | 0.040 |
Why?
|
| Homeostasis | 1 | 2003 | 950 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2013 | 5637 | 0.040 |
Why?
|
| Factor Xa | 2 | 2011 | 26 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 2 | 2008 | 249 | 0.040 |
Why?
|
| Inflammation | 2 | 2008 | 2522 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 1533 | 0.040 |
Why?
|
| Phenotype | 1 | 2008 | 6295 | 0.040 |
Why?
|
| Neointima | 1 | 2017 | 53 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 705 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 437 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 321 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2017 | 169 | 0.040 |
Why?
|
| Hypertension | 1 | 2006 | 1503 | 0.040 |
Why?
|
| Angiography | 1 | 2018 | 360 | 0.040 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2016 | 11 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 2 | 2008 | 62 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2020 | 359 | 0.030 |
Why?
|
| AC133 Antigen | 2 | 2006 | 110 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 5159 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2017 | 135 | 0.030 |
Why?
|
| New York | 1 | 2015 | 104 | 0.030 |
Why?
|
| Young Adult | 3 | 2022 | 21445 | 0.030 |
Why?
|
| Dialysis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Isoenzymes | 2 | 2010 | 614 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 119 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 544 | 0.030 |
Why?
|
| Action Potentials | 1 | 2018 | 560 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1819 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1362 | 0.030 |
Why?
|
| Anemia | 1 | 2020 | 689 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2006 | 272 | 0.030 |
Why?
|
| Endocarditis | 1 | 2016 | 125 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 793 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 2488 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 899 | 0.030 |
Why?
|
| Exercise Tolerance | 2 | 2007 | 107 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 246 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 500 | 0.030 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 12 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 1335 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 93 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 21 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2013 | 88 | 0.030 |
Why?
|
| Axillary Artery | 1 | 2013 | 33 | 0.030 |
Why?
|
| Swine | 2 | 2010 | 1541 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.030 |
Why?
|
| Troponin I | 1 | 2014 | 127 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2019 | 2450 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 700 | 0.030 |
Why?
|
| Exome | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Equipment Design | 2 | 2007 | 1204 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2006 | 747 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 3343 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2020 | 1112 | 0.030 |
Why?
|
| Myocardium | 1 | 2018 | 1313 | 0.020 |
Why?
|
| Heart | 1 | 2018 | 1223 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 289 | 0.020 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2010 | 11 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2010 | 59 | 0.020 |
Why?
|
| Risk Management | 1 | 2011 | 107 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 65 | 0.020 |
Why?
|
| Software Validation | 1 | 2010 | 32 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 31252 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 226 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 4821 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 7222 | 0.020 |
Why?
|
| Linear Models | 2 | 2003 | 1085 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3251 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 334 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 180 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 164 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 205 | 0.020 |
Why?
|
| Antidotes | 1 | 2008 | 28 | 0.020 |
Why?
|
| Streptokinase | 1 | 2007 | 25 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2008 | 132 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 2008 | 108 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2007 | 38 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 5687 | 0.020 |
Why?
|
| Ankle | 1 | 2007 | 36 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 2437 | 0.020 |
Why?
|
| Femoral Vein | 1 | 2007 | 66 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 255 | 0.020 |
Why?
|
| Cell Shape | 1 | 2006 | 128 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2013 | 908 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 621 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 423 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2006 | 311 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2007 | 182 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2005 | 92 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2006 | 495 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 87 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 259 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 527 | 0.020 |
Why?
|
| Age Distribution | 1 | 2006 | 698 | 0.020 |
Why?
|
| Lebanon | 1 | 2004 | 8 | 0.020 |
Why?
|
| Walking | 1 | 2007 | 277 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2007 | 545 | 0.020 |
Why?
|
| Ireland | 1 | 2004 | 30 | 0.020 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2003 | 17 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2003 | 48 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2004 | 209 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Cell Communication | 1 | 2006 | 509 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2003 | 78 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 121 | 0.010 |
Why?
|
| Tyrosine | 1 | 2005 | 498 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 503 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2004 | 684 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 2002 | 44 | 0.010 |
Why?
|
| International Normalized Ratio | 1 | 2002 | 48 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 664 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2002 | 55 | 0.010 |
Why?
|
| Heart Atria | 1 | 2004 | 352 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2002 | 171 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 231 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7702 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 345 | 0.010 |
Why?
|
| Adenosine | 1 | 2003 | 289 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 850 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1467 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 1183 | 0.010 |
Why?
|
| Hypolipidemic Agents | 1 | 2002 | 190 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10001 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2002 | 132 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 257 | 0.010 |
Why?
|
| Hypotension | 1 | 2002 | 210 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 323 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2002 | 259 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 1171 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 1863 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 1301 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 2440 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 3254 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 7226 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 7591 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2003 | 5319 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 15862 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 11538 | 0.000 |
Why?
|